APTO

CG-806 (BTK Inhibitor)

B-cell malignancies (NHL & CLL)

Phase 1 (Data Presentation at ASH)

Exp Date

December 5, 2020

Amp Volatility Score

Catalyst Info & Data Links

TITLE: CG-806 in B-cell malignancies

  • ClinicalTrials.gov (NCT03893682): A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas


WHAT IS THE CATALYST EVENT?

  • ASH 2020 presentation


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • December 5, 2020


PRIOR DATA/EVENTS


COMPARATIVE TABLES


PRESS RELEASE

COMPETITORS


Bruton’s tyrosine kinase (BTK) inhibitor:

  • ARQL 531 - Merck (acquired Arqule)

  • LOXO-305 - Eli Lilly and Company

  • SNSS-062 - Sunesis

  • GDC-0853 - Genentech

MARKET

  • ~77,240 people will be diagnosed with NHL in the US (source)

  • ~21,040 people will be diagnosed with CLL in the US (source)

MECHANISM OF ACTION / RATIONALE

  • CG-806 targets the ATP-binding pocket of Bruton’s tyrosine kinase (BTK), a driver of B-cell malignancy, through a reversible, non-covalent mechanism, thereby allowing CG-806 to retain low nM potency against both wildtype as well as mutant (e.g. Cys481Ser) forms of the enzyme and to exert superior potency relative to ibrutinib against primary samples from the bone marrow of patients with B-cell cancers. Of note, CG-806 inhibits phosphorylation of BTK, as well as BLK, ITK, LCK, LYN and SRC of the BCR pathway, and this allows CG-806 to hit the pathway at multiple critical nodes and to kill the B-cell cancer cells. Importantly, CG-806 does not inhibit TEC, EGFR or ErbB2 kinases which are implicated in the toxicities of other BTK inhibitors, including bleeding disorders, gut and skin toxicity, and atrial fibrillation, respectively. (Source)

Updated by HC

APTO, CG-806, B-cell_tumors, BTK Inhibitor, ASH, ASH2020

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

APTO EHA 2020 ...

APTO is presenting data at EHA 2020 for their BTK and FLT-3 inhibitor CG-806 at EHA. Get our take on the likely movement and our investment strategy going forward. CLICK HERE (Free sign-up required fo...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon